JUMPCODE GENOMICS
CRISPR-based depletion technology that removes pseudogene-derived molecules from NGS libraries to improve genetic variant detection
- Sector
- Biotech
- Total capital
- $1.1M
- Federal grants
- $384K
- 1 award · 2025
- Rank in peer group#387 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $765K
- 2 awards · Health and Human S, Agriculture
- Rank in Biotech#203 of 4373
- Granted patents
- 4
- 36 pending · first 2020
- Rank in peer group#22 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · CRISPR-based depletion method for resolving pseudogene contamination in Next Generation Sequencing (NGS) based genetic testing$384K
- Federal contractAgriculture · Hagerman, Id. Depletex Custom Primers And Custom Design Service. K.overturf$25K
- Federal contractHealth and Human S · Jumpcode Genomics, Inc. Crispr Powered Ngs Agnostic Diagnostic Aoi #10: Ngs-based Agnostic Diagnostic$740K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#22 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Keith BrownResearcherExecutive Officer, DirectorLinked by 1 patent · $384K in grants as PI
- Brandon PoeExecutive OfficerNamed in SEC Form D filings
- Court TurnerDirectorNamed in SEC Form D filings
- Dan KidleDirectorNamed in SEC Form D filings
- David Michael SalterExecutive Officer, DirectorNamed in SEC Form D filings
- David Michael SalterExecutive Officer, DirectorNamed in SEC Form D filings
Show all 14 people
- Eugene ChenDirectorNamed in SEC Form D filings
- Frank WitneyDirectorNamed in SEC Form D filings
- Joel RotroffDirectorNamed in SEC Form D filings
- Joseph LeeDirectorNamed in SEC Form D filings
- Kevin LiDirectorNamed in SEC Form D filings
- Kirk MalloyDirectorNamed in SEC Form D filings
- Michael LiangDirectorNamed in SEC Form D filings
- Yaron HakakExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingMethods And Compositions For The Making And Using Of Guide Nucleic AcidsUSPTOApplication 18923525
- PendingCreation And Use Of Guide Nucleic AcidsUSPTOApplication 18763936
- PendingMethods Selectively Depleting Nucleic Acid Using Rnase HUSPTOApplication 18834794
Show all 40 patent records
- Methods And Compositions For The Making And Using Of Guide Nucleic AcidsJul 17, 2025 · Application 18923525Pending
- Creation And Use Of Guide Nucleic AcidsJun 5, 2025 · Application 18763936Pending
- Methods Selectively Depleting Nucleic Acid Using Rnase HMay 22, 2025 · Application 18834794Pending
- Compositions And Methods For Targeted Depletion, Enrichment, And Partitioning Of Nucleic Acids Using Crispr/cas System ProteinsApr 3, 2025 · Application 18615960Pending
- Methods And Compositions For Target DetectionMar 20, 2025 · Application 18643877Pending
- Methods And Compositions For Transcriptome AnalysisMar 13, 2025 · Application 18728252Pending
- Methods For Targeted Nucleic Acid SequencingJun 6, 2024 · Application 18553167Pending
- Capture Of Nucleic Acids Using A Nucleic Acid-guided Nuclease-based SystemApr 25, 2024 · Application 18163196Pending
- Genome FractioningFeb 1, 2024 · Application 18446208Pending
- Genome FractioningSep 19, 2023 · US 11,761,039Granted
- Methods For Targeted Depletion Of Nucleic AcidsAug 24, 2023 · Application 18041041Pending
- Genome FractioningJul 25, 2023 · US 11,708,606Granted
- Methods For Analysis Of Somatic Mobile Elements, And Uses ThereofJun 22, 2023 · Application 18112239Pending
- Methods Of Sample NormalizationApr 20, 2023 · Application 17758659Pending
- Methods Of Targeted SequencingFeb 23, 2023 · Application 17758656Pending
- Sample Preparation And Sequencing Analysis For Repeat Expansion Disorders And Short Read Deficient TargetsDec 22, 2022 · Application 17770807Pending
- De-novo K-mer Associations Between Molecular StatesDec 1, 2022 · Application 17770803Pending
- Method And System For Targeted Nucleic Acid SequencingOct 20, 2022 · Application 17761866Pending
- Method For Target Specific Rna Transcription Of Dna SequencesAug 18, 2022 · Application 17724309Pending
- Method For Target Specific Rna Transcription Of Dna SequencesMay 24, 2022 · US 11,339,427Granted
- Methods For Targeted Depletion Of Nucleic AcidsMay 12, 2022 · Application 17430102Pending
- Methods And Compositions For The Making And Using Of Guide Nucleic AcidsJul 8, 2021 · Application 16995761Pending
- Genome FractioningMar 31, 2020 · US 10,604,802Granted
- Methods For Analysis Of Somatic Mobile Elements, And Uses ThereofDec 29, 2016 · Application 15121725Pending
- Method For Target Specific Rna Transcription Of Dna SequencesApplication PCTUS2017017530Pending
- Method For Target Specific Rna Transcription Of Dna SequencesApplication 62294875Pending
- Methods For Sample Preparation And Analysis Of Somatic Mobile Elements, And Uses ThereofApplication 61945791Pending
- Genome FractioningApplication 61935827Pending
- Methods For Generating Cdna Library From RnaApplication PCTUS2023073891Pending
- Methods Selectively Depleting Nucleic Acid Using Rnase HApplication PCTUS2023061880Pending
- Methods And Compositions For Transcriptome AnalysisApplication PCTUS2023060432Pending
- Methods For Targeted Nucleic Acid SequencingApplication PCTUS2022022619Pending
- Methods Selectively Depleting Nucleic Acid Using Rnase HApplication 63306934Pending
- Methods And Compositions For Transcriptome AnalysisApplication 63298866Pending
- Methods For Targeted Depletion Of Nucleic AcidsApplication PCTUS2021045521Pending
- Methods For Targeted Nucleic Acid SequencingApplication 63168831Pending
- Methods Of Sample NormalizationApplication PCTUS2021013701Pending
- Methods Of Targeted SequencingApplication PCTUS2021013598Pending
- Sample Preparation And Sequencing Analysis For Repeat Expansion Disorders And Short Read Deficient TargetsApplication PCTUS2020057163Pending
- De-novo K-mer Associations Between Molecular StatesApplication PCTUS2020056904Pending
Related companies, and why
- SECOND GENOME, INC.Similar federal contract value in Biotech · $834K in contracts
- Planet Biotechnology IncorporatedSimilar federal contract value in Biotech · $828K in contracts
- SUJANA BIOTECH, LLCSimilar federal contract value in Biotech · $783K in contracts
- GenomaticaSimilar federal contract value in Biotech · $761K in contracts
- ATUX ISKAY GROUP LLCSimilar federal contract value in Biotech · $755K in contracts
- Rigel PharmaceuticalsSimilar federal contract value in Biotech · $750K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .